Accessibility StatementSkip Navigation IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- American Healthcare REIT, Inc. (NYSE: AHR; the "Company") announced today that it has commenced an underwritten public offering of 8,100,000Â shares of its common stock on a forward basis in connection with the forward sale agreement described below. RBC Capital Markets is acting as the underwriter for the offering. In connection with the offering, the Company expects to enter into a forward sale agreement with RBC Capital ...

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company’s pre ...

PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel. Details of Cognition’s fireside discussion are as follows: E ...

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today announced that it expects to advance IKT-001 to a global pivotal Phase 3 cli ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - The article emphasizes an active investing strategy focused on identifying breakout stocks within specific price ranges, recommending to sell if prices drop below the lower boundary and to hold for gains if they surpass the upper boundary [1] Breakout Stock Identification - To identify breakout stocks, it is essential to calculate support and resistance levels, where support is the lower bound and resistance is the upper bound for stock movements [2] - Demand for a stock is lowest at its support level, while traders are more inclined to buy at the resistance level, making it crucial to focus on stocks nearing a breakout or those that have just surpassed resistance [3] Validating Breakouts - A genuine breakout occurs when the previous resistance level becomes the new support level, which can be confirmed through long-term price trend analysis [5] - The strength of support and resistance levels is determined through such studies, and correctly identifying breakout stocks can lead to significant returns [5] Screening Criteria - The screening criteria for breakout stocks include: - A percentage price change over four weeks between 10% and 20% [6] - Current price to 52-week high ratio greater than or equal to 0.9 [6] - Zacks Rank of less than or equal to 2 [6] - Beta for 60 months less than or equal to 2 [7] - Current price less than or equal to $20 [7] - These criteria narrow down the stock universe from over 6,853 to only 12 potential candidates [7] Featured Breakout Stocks - Orla Mining Ltd. (ORLA) focuses on acquiring, exploring, and developing mineral properties, with an expected earnings growth rate of 212% for the current year and a Zacks Rank of 2 [9] - FIGS, Inc. (FIGS) operates as a direct-to-consumer healthcare apparel company, with an expected earnings growth rate of 400% for the current year and a Zacks Rank of 1 [10] - Compass Therapeutics, Inc. (CMPX) is a clinical-stage oncology biopharmaceutical company with an expected earnings growth rate of 16.7% for the next quarter and a Zacks Rank of 2 [11]

Core Insights - Youdao, Inc. reported an earnings per share (EPS) of $0.011, surpassing the estimated EPS of -$0.00007 [1][6] - The company achieved a net revenue of approximately $228.8 million in Q3 2025, exceeding estimates and reflecting a 3.6% year-over-year increase [2][6] - Youdao's strategic investments in Youdao Lingshi and online marketing services have driven significant growth, with online marketing services seeing a 51.1% year-over-year increase in net revenues [3][6] Financial Performance - The operating profit for the first three quarters of 2025 grew nearly 150% year-over-year, attributed to the "AI-Native" strategy [2] - Youdao Lingshi experienced over 40% year-over-year growth in gross billings [3] - The company's price-to-earnings (P/E) ratio is approximately 33.83, and the price-to-sales ratio stands at about 1.37 [4] Financial Structure - Youdao has a negative debt-to-equity ratio of -0.89, indicating a unique financial structure, yet has maintained profitability for five consecutive quarters [5] - The current ratio of 0.55 reflects the company's ability to cover its short-term liabilities with its short-term assets [5]

CALGARY, Alberta, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted the Corporation’s notice of intention to make a normal course issuer bid (the “NCIB”). The NCIB allows Birchcliff to purchase up to 26,769,197 common shares, which is equal to 10% of Birchcliff’s public float of 267,691,970 common shares as of November 13, 2025. On November 13, 2025, Birchcliff had 273,379,95 ...

Core Insights - NVIDIA reported record revenue of $57 billion for the third quarter, exceeding Wall Street expectations and providing a positive forecast amid concerns about an AI bubble [2][3] - The company anticipates total revenue of approximately $203 billion for 2025, with the current quarter projected to reach $65 billion, reflecting a 65% year-over-year growth [3] - CEO Jensen Huang emphasized strong demand for AI chips and highlighted a sales pipeline worth half a trillion dollars for 2025 and 2026 [2][3] Financial Dynamics - NVIDIA's optimistic outlook includes expectations of around $500 billion in revenue potential from AI chips in 2025-2026, supported by significant investments in customer companies [7] - The company announced a potential investment of up to $100 billion in OpenAI, aimed at expanding data center capacity and ensuring a return flow to NVIDIA [8] - NVIDIA also invested $1 billion in Nokia to collaborate on AI-driven telecommunications and 6G technology, which may lead to further purchases of NVIDIA hardware [9] Investment Strategy - NVIDIA has engaged in over 50 venture capital deals in 2025, investing $23.7 billion in AI companies, with many recipients likely using funds to purchase NVIDIA chips [10] - Critics argue that this creates a circular financing dynamic, where NVIDIA's investments enable recipients to buy its chips, potentially masking underlying risks [11] Insider Activity - There has been a notable increase in insider stock sales at NVIDIA in 2025, with 258 trades totaling approximately -$221.8 million, coinciding with a 6.6% rise in stock price [12] - The uptick in insider selling may indicate executives sensing peak valuations, suggesting that investors should consider realizing gains and reducing exposure [12] Market Position - NVIDIA's growth is driven by AI's transformative potential, but the interplay of circular financing and insider selling raises questions about the sustainability of its rally [13] - Investors are encouraged to reassess their positions and consider trimming or diversifying their holdings as the market dynamics evolve [13]

Kidoz delivers record results, reinvests in technologyto support scale up growth phase. VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / Kidoz Inc. (TSXV:KDOZ)(OTCQB:KDOZF) (the "Company"), developer of the global AdTech platform delivering safe privacy-first, mobile gamer engagement at scale, announced today its unaudited condensed interim financial results for the quarter ended September 30, 2025. ...